Equities

Harvard Bioscience Inc

Harvard Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.77
  • Today's Change-0.01 / -0.36%
  • Shares traded1.00
  • 1 Year change-34.67%
  • Beta1.2986
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

  • Revenue in USD (TTM)101.13m
  • Net income in USD-10.68m
  • Incorporated2000
  • Employees391.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DIH Holding US Inc67.62m-6.14m85.14m192.00------1.26-0.1903-0.19031.96-0.98411.994.1211.80352,161.50-18.09------48.86---9.09--0.4221-3.38----19.26---732.64------
Monogram Technologies Inc365.00k-11.69m90.03m28.00--12.77--246.67-0.3745-0.37450.01180.22240.0239----13,035.71-76.61-119.26-117.14-257.400.00---3,203.87-5,045.60----0.00-------0.3964---15.97--
Pro-Dex Inc53.84m2.13m92.75m148.0045.443.0128.221.720.60790.607915.219.181.032.504.52363,810.804.0812.335.2015.3027.0231.263.9512.131.661.580.27840.0016.8314.66-69.93-12.47-6.80--
Sensus Healthcare Inc36.37m6.65m96.86m35.0014.521.8314.112.660.40720.40722.233.230.66011.102.651,039,057.0012.0610.2913.2512.1460.2362.8518.2715.298.20--0.00---45.20-1.58-98.00---23.16--
Cibus Inc2.96m-291.86m101.66m183.00--0.3301--34.33-16.39-16.390.154511.750.0043--3.0916,180.33-53.70-86.28-64.26-96.45-----12,400.74-792.07---2.660.0032--1,057.3350.41-1,484.44--18.53--
Edap Tms SA (ADR)69.25m-21.95m113.60m307.00--2.14--1.64-0.5919-0.59191.871.430.69922.373.42225,578.70-22.16-6.62-31.50-9.2240.3443.23-31.69-9.591.80--0.0599--9.649.05-622.06--32.75--
Myomo Inc21.11m-9.45m115.76m101.00--11.95--5.48-0.2614-0.26140.58330.32041.433.5010.13209,020.40-64.07-81.78-101.11-115.2767.3568.50-44.75-85.761.94--0.00--23.7051.0924.00--2.82--
Fonar Corp102.72m10.29m116.77m561.0011.750.70456.191.141.481.4814.7224.700.502319.991.41183,098.207.168.737.409.6045.5548.3314.2616.399.16--0.0051--1.083.89-24.71-15.058.48--
KORU Medical Systems Inc30.82m-11.76m117.85m82.00--6.30--3.82-0.2574-0.25740.67420.40820.97372.946.50375,817.30-37.15-17.60-43.48-20.2962.4959.44-38.16-21.703.27--0.0195--2.2310.44-58.65--11.10--
EUDA Health Holdings Ltd3.71m-8.44m120.49m106.00------32.51-0.3685-0.43840.1707-0.30450.2752--3.5534,966.61-62.62------22.72---227.57-----1.49-----1.54--66.17------
Harvard Bioscience, Inc.101.13m-10.68m121.24m391.00--1.80--1.20-0.2471-0.24712.351.540.74411.646.88258,631.70-7.86-3.29-9.44-3.8958.3956.67-10.56-4.570.9416-1.310.3467---0.9573-1.4564.11--18.10--
908 Devices Inc.52.69m-37.99m133.08m230.00--0.8505--2.53-1.15-1.151.604.520.25111.544.95229,069.60-18.11-14.16-20.12-15.3552.3253.02-72.10-64.254.23--0.00--7.2117.89-8.45--22.98--
InfuSystem Holdings Inc129.37m366.00k136.42m499.00408.682.5510.891.050.01570.01575.992.511.2210.386.44259,264.500.34654.600.4015.6949.6856.430.28294.071.641.970.38980.0014.4413.384,744.44--6.01--
Akoya Biosciences Inc93.22m-60.35m144.04m330.00--6.47--1.55-1.22-1.221.890.44980.56051.936.34282,472.70-36.29---45.98--57.57---64.74--1.98-8.000.7755--29.09--10.36------
Acme United Corp192.71m19.45m157.55m645.008.581.526.300.81764.974.9748.5928.131.152.074.83298,770.5011.607.0913.798.2939.4035.7210.095.501.776.600.262118.81-1.276.88486.3131.089.024.84
Data as of Sep 19 2024. Currency figures normalised to Harvard Bioscience Inc's reporting currency: US Dollar USD

Institutional shareholders

46.18%Per cent of shares held by top holders
HolderShares% Held
Punch & Associates Investment Management, Inc.as of 30 Jun 20242.77m6.36%
BlackRock Fund Advisorsas of 30 Jun 20242.59m5.93%
Harvey Partners LLCas of 30 Jun 20242.56m5.86%
AMH Equity Ltd.as of 30 Jun 20242.20m5.04%
The Vanguard Group, Inc.as of 30 Jun 20242.08m4.76%
Granahan Investment Management, LLCas of 30 Jun 20241.93m4.42%
Dimensional Fund Advisors LPas of 30 Jun 20241.71m3.92%
272 Capital LPas of 30 Jun 20241.54m3.52%
Royce & Associates LPas of 30 Jun 20241.44m3.31%
Boothbay Fund Management LLCas of 30 Jun 20241.34m3.06%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.